Marker Therapeutics (NASDAQ: MRKR)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Marker Therapeutics (NASDAQ: MRKR) through any online brokerage.
Other companies in Marker Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), T2 Biosystems (NASDAQ:TTOO), Larimar Therapeutics (NASDAQ:LRMR) and VistaGen Therapeutics (NASDAQ:VTGN).
The latest price target for Marker Therapeutics (NASDAQ: MRKR) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting MRKR to rise to within 12 months (a possible 916.26% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Marker Therapeutics (NASDAQ: MRKR) is $0.3936 last updated August 12, 2022, 8:00 PM UTC.
The next Marker Therapeutics (MRKR) dividend date is projected to be Thursday, September 1, 2022.
Marker Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Marker Therapeutics.
Marker Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.